Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 284

1.

Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.

Ellingsen T, Hansen I, Thorsen J, Møller BK, Tarp U, Lottenburger T, Andersen LS, Skjødt H, Pedersen JK, Lauridsen UB, Svendsen A, Lindegaard H, Jacobsen S, Østergaard M, Vestergaard A, Jurik AG, Junker P, Christensen AF, Hetland ML, Hørslev-Petersen K, Stengaard-Pedersen K.

Scand J Rheumatol. 2014;43(2):91-100. doi: 10.3109/03009742.2013.803149. Epub 2013 Aug 28.

PMID:
23980529
2.

Up-regulated dipeptidyl-peptidase IV (CD26) on monocytes was unaffected by effective DMARD treatment in early steroid and DMARD-naive rheumatoid arthritis.

Ellingsen T, Hansen I, Thorsen J, Kuno Møller B, Tarp U, Jacobsen S, Lund Hetland M, Vestergaard A, Hørslev-Petersen K, Stengaard-Pedersen K.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1):58-63. Epub 2012 Mar 6.

PMID:
22273590
3.

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.

Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M, Deleuran B.

Scand J Rheumatol. 2014;43(2):101-8. doi: 10.3109/03009742.2013.823517. Epub 2013 Nov 1.

PMID:
24182347
4.

MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).

Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M; CIMESTRA study group.

Ann Rheum Dis. 2009 Mar;68(3):384-90. doi: 10.1136/ard.2008.088245. Epub 2008 Apr 3.

PMID:
18388160
5.

Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial.

Hetland ML, Stengaard-Pedersen K, Junker P, Østergaard M, Ejbjerg BJ, Jacobsen S, Lottenburger T, Hansen I, Tarp U, Andersen LS, Svendsen A, Pedersen JK, Lauridsen UB, Ellingsen T, Lindegaard H, Pødenphant J, Vestergaard A, Jurik AG, Hørslev-Petersen K; CIMESTRA study group.

Ann Rheum Dis. 2010 Oct;69(10):1789-95. doi: 10.1136/ard.2009.125534. Epub 2010 May 5.

PMID:
20444751
6.

Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.

Salaffi F, Carotti M, Ciapetti A, Gasparini S, Filippucci E, Grassi W.

BMC Musculoskelet Disord. 2011 May 30;12:120. doi: 10.1186/1471-2474-12-120.

7.

Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression.

Nishina N, Kaneko Y, Kameda H, Kuwana M, Takeuchi T.

Clin Rheumatol. 2013 Nov;32(11):1661-6. doi: 10.1007/s10067-013-2309-0. Epub 2013 Jun 11.

PMID:
23754245
8.

Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.

Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.

J Rheumatol. 2014 Dec;41(12):2352-60. doi: 10.3899/jrheum.131299. Epub 2014 Oct 1.

PMID:
25274894
9.

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.

Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.

J Rheumatol. 2011 Nov;38(11):2362-8. doi: 10.3899/jrheum.110054. Epub 2011 Sep 1.

10.

Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.

Combe B, Rincheval N, Benessiano J, Berenbaum F, Cantagrel A, Daurès JP, Dougados M, Fardellone P, Fautrel B, Flipo RM, Goupille P, Guillemin F, Le Loët X, Logeart I, Mariette X, Meyer O, Ravaud P, Saraux A, Schaeverbeke T, Sibilia J.

J Rheumatol. 2013 Oct;40(10):1650-7. doi: 10.3899/jrheum.121515. Epub 2013 Aug 15.

PMID:
23950185
11.

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.

Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, Kvien TK.

Ann Rheum Dis. 2008 Feb;67(2):212-7. Epub 2007 May 25.

PMID:
17526555
12.

Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids.

Sanmartí R, Gómez-Centeno A, Ercilla G, Larrosa M, Viñas O, Vazquez I, Gómez-Puerta JA, Gratacós J, Salvador G, Cañete JD.

Clin Rheumatol. 2007 Jul;26(7):1111-8. Epub 2006 Nov 16.

PMID:
17109060
13.

Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage.

Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B.

Ann Rheum Dis. 2003 Feb;62(2):120-6.

14.

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.

Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, Forslind K, van Vollenhoven RF; SWEFOT study group.

Ann Rheum Dis. 2015 Aug;74(8):1509-14. doi: 10.1136/annrheumdis-2013-204601. Epub 2014 Apr 4.

15.

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.

Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

17.

Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis.

Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Jørgensen A, Hvid M, Deleuran B.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4):689-92. Epub 2011 Sep 1.

PMID:
21813065
18.

Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.

Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X.

Arthritis Res Ther. 2012 Nov 19;14(6):R249. doi: 10.1186/ar4092.

19.

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.

Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.

Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29.

PMID:
21640044
20.
Items per page

Supplemental Content

Write to the Help Desk